← Back to Search

Neuromodulation

Brain Zapping for ADHD

N/A
Recruiting
Led By Joan Camprodon, MD, PhD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female subjects 18-66 years of age
Be older than 18 years old
Must not have
Current or past history of clinically unstable psychiatric conditions such as suicidal or homicidal behavior or psychotic disorders
Ongoing treatment with any psychotropic medications for healthy controls
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change before and after stimulation on each of the three visits, average 2-6 weeks
Awards & highlights

Summary

This trial will use brain zapping to study the effects of tDCS on executive function and inhibitory control in patients with ADHD compared to healthy controls.

Who is the study for?
This trial is for English-speaking adults aged 18-66 with ADHD, diagnosed per DSM-5 criteria. Participants can be on stimulants but must stop them two days before each study visit. Excluded are those with unstable psychiatric conditions, metal implants in the head/neck, brain stimulators, or who are pregnant/nursing.
What is being tested?
The study tests how transcranial direct current stimulation (tDCS) affects executive function and self-control in adults with ADHD compared to healthy individuals. It examines the temporary changes caused by this non-invasive brain stimulation technique.
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site, itching or tingling during stimulation, headache, fatigue, nausea or dizziness. Serious risks like seizures are rare but possible in susceptible individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 66 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have a history of severe mental health issues like suicidal thoughts or psychosis.
Select...
I am currently taking medication for mental health.
Select...
I do not have any psychiatric or neurological disorders.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change before and after stimulation on each of the three visits, average 2-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change before and after stimulation on each of the three visits, average 2-6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Accuracy and Reaction Time in Attention and Working Memory
Change in Accuracy and Reaction Time in Inhibition/Decision Making
Secondary study objectives
Amplitude of Encephalogram (EEG) Event Related Potentials

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Healthy ControlExperimental Treatment1 Intervention
Volunteers without Neuropsychiatric Disorders.
Group II: ADHDExperimental Treatment1 Intervention
Patients with ADHD.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,993 Previous Clinical Trials
13,230,601 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,419 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joan Camprodon, MD, PhD, MPHPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
864 Total Patients Enrolled
2 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
704 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

tDCS (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT04175028 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Healthy Control, ADHD
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: tDCS Highlights & Side Effects. Trial Name: NCT04175028 — N/A
tDCS (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04175028 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT04175028 — N/A
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top